STAT+：基因疗法长期争议的致癌风险成为现实

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The tumors possibly connected to pediatric gene therapies make me sad. Babies. 

The need-to-know this morning

• Vir Biotechnology said monthly injections of two experimental medicines reduced hepatitis D virus to undetectable levels in 44% of patients compared to none of the patients who received delayed treatment with the same regimen. The result achieved the primary goal of a Phase 3 study. 
• Zura Bio said its experimental antibody tibulizumab failed to improve the symptoms of hidradenitis suppurativa, an inflammatory skin condition, compared to a placebo in a mid-stage study. 
• Roivant said Lisraya generated $31 million in sales in the five weeks since it was approved to treat dermatomyositis.
• Argenx is acquiring privately held Unnatural Products, a medicinal chemistry company that specializes in the discovery of protein-based drugs. 

Why two heart trials should puncture AI drug discovery enthusiasm

Before anyone promises that AI will cure every disease, consider what happened the last time a shiny new tool was supposed to make drug development more predictable. At the American Heart Association meeting, two big trials came up empty.

Continue to STAT+ to read the full story…

注意转载授权 · 阅读原文